All In Biotech

Drug Trial Radar · NCT07207395

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

A Study of Open-label Orally Administered JBI-802 Alone or in Combination With Pembrolizumab in Patients With Advanced NSCLC Tumors Harboring an STK11 Mutation

Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
The Christ HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

Conditions

  • Lung Cancer (NSCLC)

Interventions

  • JBI-802Drug

    LSD1/HDAC6 Inhibitor

  • PembrolizumabDrug

    PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Up to 28 days after last dose of study drug
  2. Investigator Assessed ORRTime frame: Up to 28 days from last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Christ Hospital

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.